

ROSSARI BIOTECH TRADING FZE
Jebel Ali Free Zone, Dubai, U.A.E.
FINANCIAL STATEMENTS
For the period ended 31 March, 2025

FINANCIAL STATEMENTS & INDEPENDENT AUDITORS REPORT
FOR THE PERIOD ENDED 31 MARCH 2025

ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

<u>Particular</u>	<u>INDEX</u>	<u>Page number</u>
General informations		1
Manager's report		2-3
Independent auditors report		4-6
Statement of financial position		7
Statement of profit or loss and other comprehensive income		8
Statement of cash flow		9
Statement of changes in equity		10
Notes to the financial statements		11-19
Statement of property, plant and equipments		20

ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

GENERAL INFORMATION

Shareholder : Rossari Global DMCC

Manager : Rupeshkumar Haridas Ruparelia

License No : 110741907

Principal activities of the Entity:

- 1 Packing & Packaging Materials Trading,
- 2 Medicinal Chemical Trading,
- 3 Detergents & Disinfectants Trading,
- 4 Industrial Solvents Trading,
- 5 Tannery & Dyeing Materials Trading,
- 6 Acids & Alkalines Trading,
- 7 Oilfield Chemicals Trading,
- 8 Basic Industrial Chemicals Trading,
- 9 Insecticides Trading,
- 10 Industrial Plant Equipment & Spare Parts Trading,
- 11 Oilfield Chemicals Trading,
- 12 Medical, Surgical Equipment & Instruments Trading,
- 13 Scrap & Metal Waste Trading,
- 14 General Trading.

Bank : CITI Bank

Business Address : LB181407A, Jebel Ali Freezone,
Dubai, United Arab Emirates

Auditor : Coast Accounting and Auditing
P.O. Box 45341
Dubai, United Arab Emirates

ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

MANAGER'S REPORT

The Manager has pleasure in presenting his report and the financial statements for the period ended 31 March 2025.

Principal activity of the Entity:

- 1 Packing & Packaging Materials Trading,
- 2 Medicinal Chemical Trading,
- 3 Detergents & Disinfectants Trading,
- 4 Industrial Solvents Trading,
- 5 Tannery & Dyeing Materials Trading,
- 6 Acids & Alkalines Trading,
- 7 Oilfield Chemicals Trading,
- 8 Basic Industrial Chemicals Trading,
- 9 Insecticides Trading,
- 10 Industrial Plant Equipment & Spare Parts Trading,
- 11 Oilfield Chemicals Trading,
- 12 Medical, Surgical Equipment & Instruments Trading,
- 13 Scrap & Metal Waste Trading,
- 14 General Trading.

Financial review:

The table below summarizes the results for the period from 07.10.2024 to 31.03.2025:

(figures in U.A.E Dirhams)

<u>Particulars</u>	<u>From 07.10.2024</u> <u>to 31.03.2025</u>
Revenue	1,579,175
Gross profit for the period	287,712
Net profit for the period	145,508
Net profit %	9.21%

Events after year end:

In the opinion of the Manager, no transaction or event of a material and unusual nature, favorable or unfavorable, has arisen in the interval between the end of the financial year and the date of this report that is likely to affect, substantially, the result of the operations or the financial position of the Entity.

Auditor:

M/s Coast Accounting & Auditing Chartered Accountants, have showed their willingness to continue and are appointed to carry out independent audit for the year ending 31 March 2026.

(cont...)

ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Statement of Manager's responsibilities:

The applicable requirements require the manager to prepare the financial statements for each financial year, which presents fairly, in all material respects, the financial position of the Entity, and its financial performance for the year then ended.

The audited financial statements for the period under review have been prepared in conformity and in compliance with the relevant statutory requirements and other governing laws. The Manager confirms that sufficient care has been taken for the maintenance of proper and adequate accounting records that disclose with reasonable accuracy at any time, the financial position of the Entity and enables him to ensure that the financial statements comply with the requirements of applicable statute. She also confirms that appropriate accounting policies have been selected and applied consistently in order that the financial statements reflect fairly the form and substance of the transactions carried out during the year under review and reasonably present the Entity's financial conditions and results. These financial statements were approved by the shareholders and signed on behalf by the authorized representative of the company.

For ROSSARI BIOTECH TRADING FZE

Manager

INDEPENDENT AUDITOR'S REPORT

To,
The Shareholder,
ROSSARI BIOTECH TRADING FZE
LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **ROSSARI BIOTECH TRADING FZE, Jebel Ali Free Zone, Dubai, United Arab Emirates** ("Entity") which comprise the statement of financial position as at 31 March 2025, and the statement of profit or loss and other comprehensive income, statement of changes in equity, statement of cash flows for the period then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at 31 March 2025 and its financial performance and its cash flows for the period then ended in accordance with International Financial Reporting Standards (IFRSs).

Basis of Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the requirements of Code of Ethics for Professional Accountants, issued by International Ethics Standards Board for Accountants (IESBA) together with ethical requirements that are relevant to our audit of the financial statements and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Other matter

This period is the first period of operations.

(Cont..)



ROSSARI BIOTECH TRADING FZE - 31 March 2025**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- We communicate with the management regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

(Cont..)



ROSSARI BIOTECH TRADING FZE - 31 March 2025

Auditor's Responsibilities for the Audit of the Financial Statements (Cont...)

Report on other legal and regulatory requirements

We further confirm that,

- 1 Compliance with UAE Law No. 2 of 1986 and Jebel Ali Free Zone Companies Implementing Regulations 2016.
- 2 We have obtained all the information and explanations which we considered necessary for our audit,
- 3 The financial statements have been prepared and comply in all material respects with the applicable provisions of the relevant U.A.E. laws, and the Memorandum and Articles of Association of the Entity,
- 4 The contents of the Manager's report which relates to the financial statements are in agreement with the company's books of account.

COAST ACCOUNTING & AUDITING

Chartered Accountants



R.I.Bhatia

Reg. No. 174, United Arab Emirates
Ministry of Economy (Audit Division)

Date: 24 April 2025

ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Statement of Financial Position as at 31 March 2025

		(figures in U.A.E Dirhams)
		<u>From 07.10.2024</u>
	<u>Notes</u>	<u>to 31.03.2025</u>
Assets		
<i>Non - Current assets</i>		
Property, plant and equipments	4	110,813
Total non - current assets		110,813
<i>Current assets</i>		
Trade receivables	5	1,579,175
Other current assets	6	55,286
Cash and cash equivalents	7	85,652
Total current assets		1,720,113
Total assets		1,830,926
Equity and liabilities		
<i>Equity</i>		
Share capital	8	100,000
Retained earnings	9	145,508
Total equity		245,508
<i>Current liabilities</i>		
Due to related parties	10	1,445,260
Trade and other payables	11	140,158
Total current liabilities		1,585,418
Total liabilities		1,585,418
Total equity and liabilities		1,830,926

The attached notes form an integral part of these accounts.

Auditors report is annexed hereto.

We approve these financial statements and confirm that we are responsible for them, including selecting the accounting policies and making the judgment underlying them. We also confirm that we have made available all relevant accounting records and information for their compilation.

For ROSSARI BIOTECH TRADING FZE

Authorized Signatory



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Statement of Profit or Loss and Other Comprehensive Income for the period ended 31 March 2025

		(figures in U.A.E Dirhams)
		<u>From 07.10.2024</u>
	<u>Notes</u>	<u>to 31.03.2025</u>
Revenue	12	1,579,175
Cost of revenue	13	(1,291,463)
Gross profit for the period		287,712
General and administrative expenses	14	(84,872)
Finance cost	15	(56,141)
Depreciation	4	(1,191)
Net profit for the period		145,508
Total comprehensive profit for the period		145,508

The attached notes form an integral part of these accounts.

Auditors report is annexed hereto.

We approve these financial statements and confirm that we are responsible for them, including selecting the accounting policies and making the judgment underlying them. We also confirm that we have made available all relevant accounting records and information for their compilation.

For ROSSARI BIOTECH TRADING FZE

Authorized Signatory



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Statement of Cash Flow for the period ended 31 March 2025

(figures in U.A.E Dirhams)

		<u>From 07.10.2024</u>
	<u>Notes</u>	<u>to 31.03.2025</u>
<u>Cash Flow from operating activities</u>		
Net profit for the period		145,508
Adjusted by:		
Depreciation	4	1,191
Net cash from operating activities		146,699
<u>Changes in working capital</u>		
Trade receivables	5	(1,579,175)
Other current assets	6	(55,286)
Trade and other payables	11	140,158
Net cash flow (used in) operating activities		(1,347,604)
<u>Cash Flow from investing activities</u>		
Purchase of property, plant and equipments	4	(112,004)
Net cash (used in) investing activities		(112,004)
<u>Cash Flow from financing activities</u>		
Capital introduced	8	100,000
Loans from related parties	10	1,445,260
Net cash flow from financing activities		1,545,260
<u>Net increase in cash and cash equivalents</u>		85,652
Cash and cash equivalents at the beginning of the year		-
Cash and cash equivalents at the end of the year		85,652
Represented by:	7	
Bank balance		85,652
		85,652

The attached notes form an integral part of these accounts.

Auditors report is annexed hereto.

For ROSSARI BIOTECH TRADING FZE

Authorized Signatory



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Statement of Changes in Equity for the period ended 31 March 2025

(figures in U.A.E Dirhams)

	<u>Share Capital</u>	<u>Retained Earnings</u>	<u>Total</u>
<u>Changes in Equity</u>			
a. Share capital introduced	100,000	-	100,000
b. Net profit for the period	-	145,508	145,508
Balance at 31 March 2025	<u>100,000</u>	<u>145,508</u>	<u>245,508</u>

The attached notes form an integral part of these accounts.
Auditors report is annexed hereto.

For ROSSARI BIOTECH TRADING FZE

Authorized Signatory



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

1 LEGAL STATUS :

ROSSARI BIOTECH TRADING FZE, Jebel Ali Free Zone, Dubai, United Arab Emirates was incorporated on October 07, 2024 and operate as a Free Zone Entity under a License No. 110741907, issued by the Jebel Ali Free Zone Authority, Dubai, UAE. The license is issued and based upon UAE Law No. 2 of 1986 and Jebel Ali Free Zone Companies Implementing Regulations 2016.

The registered address of the company is LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

The Manager of the company is Mr. Rupeshkumar Haridas Ruparelia, having Passport No. Z5023327. Nationality India.

As per UAE Cabinet Decision 52 of 2017 on the Executive regulations of the Federal Decree Law No. (8) of 2017, Value Added Tax was introduced in the UAE, company is not registered under VAT law.

2 BUSINESS ACTIVITIES :

The main activities of the Company are Packing & Packaging Materials Trading, Medicinal Chemical Trading, Detergents & Disinfectants Trading, Industrial Solvents Trading, Tannery & Dyeing Materials Trading, Acids & Alkalines Trading, Oilfield Chemicals Trading, Basic Industrial Chemicals Trading, Insecticides Trading, Industrial Plant Equipment & Spare Parts Trading, Oilfield Chemicals Trading, Medical, Surgical Equipment & Instruments Trading, Scrap & Metal Waste Trading, General Trading.

3 SIGNIFICANT ACCOUNTING POLICIES :

(a) Basis of preparation:

The financial statements are prepared under the historical cost convention basis applied consistently. Accrual basis of accounting has been followed by the company for the financial statements except the cash flow. These financial statements are prepared on the assumption of going concern basis.

(b) Statement of compliance

The Financial Statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as promulgated by the International Accounting Standard Board ("IASB"), interpretations issued by the International Financial Reporting Interpretation Committee ("IFRIC") and requirements of the rules and regulations of UAE. The license is issued and based upon UAE Law No. 2 of 1986 and Jebel Ali Free Zone Companies Implementing Regulations 2016.

(cont...)



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

Significant Accounting Policies : (cont.. page 11)

(c) Revenue recognition:

IFRS 15 Revenue from Contracts with Customers outlines a single comprehensive model of accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance found across several Standards and Interpretations within IFRSs. It establishes a new five-step model that will apply to revenue arising from contracts with customers.

Step 1 *Identify the contract with a customer:* A contract is defined as an agreement between two or more parties that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations.

Step 2 *Identify the performance obligations in the contract:* A performance obligation in a contract is a promise to transfer a good or service to the customer.

Step 3 *Determine the transaction price:* Transaction price is the amount of consideration to which the Entity expects to be entitled in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties.

Step 4 *Allocate the transaction price to the performance obligations in the contract:* For a contract that has more than one performance obligation, the Entity will allocate the transaction price to each performance obligation in an amount that depicts the consideration to which the Entity expects to be entitled in exchange for satisfying each performance obligation.

Step 5 Recognise revenue as and when the Entity satisfies a performance obligation.

(d) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the establishment's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the establishment's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

(e) Property, Plant and Equipment

Property and equipment are stated at cost less accumulated depreciation and impairment losses. The cost less estimated residual value, where material, is depreciated using the straight-line method from the date of acquisition to the estimated useful lives of the assets as follows:



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

Significant Accounting Policies : (cont.. page 12)

<u>Particulars</u>	<u>Life of Assets</u>
Building	30
Furniture and fixtures	10
Office equipments	5
Electrical equipments	10

At the end of each reporting period, management conducts an assessment of property and equipment to determine whether there are any indications that assets may be impaired. In the absence of such indications, no further action is taken. If such indications do exist, an analysis of each asset is undertaken to determine its net recoverable amount and, if this is below its carrying amount, a provision is made through comprehensive income statement.

(f) Trade receivables

Trade receivables are shown at their carrying value in the balance sheet. The management is of the opinion that these are fully recoverable. Bad debts are accounted when there is default from customer and all means of recovery have failed. No provision has been made in these accounts for bad and doubtful accounts.

(g) Significant accounting estimates and assumptions

The preparation of financial statements in conformity with IFRS requires the use of estimates and assumptions that effect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements , and the reported amounts of revenues and expenses during the reported periods. Accounting estimates are employed in the financial statements to determine reported amounts, including the recoverability of certain assets, the useful lives of tangible and intangible assets and other assets. Although these estimates are based on management's best knowledge of current events and actions, actual results may ultimately vary from those estimates.

(h) Adoption of new IFRS

A number of new standards are effective for annual periods beginning after 1 January 2024 and earlier application is permitted, however, the Company has not early adopted the new or amended standards in preparing these Financial statements. The following new or amended standards that are adopted in annual periods beginning on 1 January 2024:

(i) New standards, interpretations and amendments adopted by the Company Effective date

• Amendment to IFRS 16 – Leases on sale and leaseback

These amendments include requirements for sale and leaseback transactions in IFRS 16 to explain how an entity accounts for a sale and leaseback after the date of the transaction. Sale and leaseback transactions where some or all the lease payments are variable lease payments that do not depend on an index or rate are most likely to be impacted.

(cont...)



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

Significant Accounting Policies : (cont.. page 13)

• Amendment to IAS 1 – Non-current liabilities with covenants

These amendments clarify how conditions with which an entity must comply within twelve months after the reporting period affect the classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these conditions.

• Amendment to IAS 7 and IFRS 7 - Supplier finance

These amendments require disclosures to enhance the transparency of supplier finance arrangements and their effects on an entity's liabilities, cash flows and exposure to liquidity risk. The disclosure requirements are the IASB's response to investors' concerns that some companies' supplier finance arrangements are not sufficiently visible, hindering investors' analysis.

The application of these revised IFRSs has not had any material impact on the amounts reported for the current and prior years but may affect the accounting for future transactions or arrangements.

(ii) Standards, amendments and interpretations in issue but not effective

The following amended standards and interpretations are not expected to have a significant impact on the Company Financial Statements:

Forthcoming requirements	Effective date
IFRS S1 General Requirements for Disclosure of Sustainability-related Financial Information and IFRS S2 Climate-related Disclosures	1 January 2024
Sale or Contribution of Assets between an Investor its Associates or Joint Venture (Amendments to IFRS 10 and IAS 28)	Effective date deferred indefinitely
Lack of Exchangeability – Amendments to IAS 21	1 January 2025
Presentation and Disclosure in Financial Statements issued (IFRS 18)**	1 January 2027

**IFRS 18 Presentation and Disclosure in Financial Statements - The IASB issued IFRS 18 Presentation and Disclosure in Financial Statements in April 2024. IFRS 18 aims to improve how companies communicate in their financial statements, with a focus on information about financial performance in the statement of profit or loss. IFRS 18 is accompanied by limited amendments to the requirements in IAS 7 Statement of Cash Flows. IFRS 18 is effective from 1 January 2027. IFRS 18 replaces IAS 1 Presentation of Financial Statements and will affect the presentation and disclosure of financial performance in the Company financial statements when adopted.

The Company does not expect the adoption of the above new standards, amendments and interpretations to have a material impact on the future financial statements of the Company.

(cont...)



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

Significant Accounting Policies : (cont.. page 14)

(i) Foreign currency translation

Transaction in currencies other than the company functional currency (Foreign Currencies) are recorded at the rates of exchange prevailing on the dates of transactions. Monetary items denominated in foreign currencies are re-translated at the rates prevailing on the balance sheet date. non-monetary items carried at fair value that are denominated in foreign currencies are re-translated at the rates prevailing on the date when the fair value was determined the resultant income or gain is shown in the income statement.

(j) Cash and cash equivalents

Cash and cash equivalents for the purpose of statement of cash flows is bank balance only.

(k) Reporting currency and rounding up

The functional currencies are U.A.E. Dirhams and US Dollars. The reporting currency is U.A.E. Dirhams. The figures are rounded up to Dirhams ignoring fils.

(figures in U.A.E Dirhams)

From 07.10.2024 to

31.03.2025

4 PROPERTY, PLANT AND EQUIPMENTS

110,813

(See a separate schedule on page no. 20)

5 TRADE RECEIVABLES

Trade receivables

1,579,175

1,579,175

6 OTHER CURRENT ASSETS

Prepayments

55,286

55,286

7 CASH AND CASH EQUIVALENTS

Bank balance

85,652

85,652

8 SHARE CAPITAL

Authorized, issued and paid up share capital of the company is AED 100,000 divided in 100 shares of AED 1,000 each. The name of the shareholder and its contribution in the capital is as follows :

<u>Name of shareholder</u>	<u>Domicile</u>	<u>%of shares</u>	<u>Share Capital</u>
1 Rossari Global DMCC	U.A.E	100%	100,000
		<u>100%</u>	<u>100,000</u>



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

Significant Accounting Policies : (cont.. page 15)

(figures in U.A.E Dirhams)

From 07.10.2024 to

31.03.2025

9 RETAINED EARNINGS

Net profit for the period	145,508
Closing balance	<u>145,508</u>

10 DUE TO RELATED PARTIES

The company entered into transactions with companies that fall within the definition of a (related party) Associated parties as contained in International Accounting Standards (IAS). The parties comprise common ownership and or common management and control over the parties. The transaction is in nature of borrowings given.

Details of transactions between the company and its related parties are disclosed below:

<u>Related Party</u>	<u>Nature of Transaction</u>	
Loan from Rossari Global DMCC	Parent company	1,400,000
Interest Payable -Rossari Global DMCC	Parent company	45,260
		<u>1,445,260</u>

Note : Loan Borrowed from Parent Company

The Company has obtained loans from its parent company at an interest rate of 10%, determined on an arm's length basis. The terms and conditions of the loan are in line with standard market practices. As the interest rate matches that of the loans issued to subsidiaries, there is no resultant gain or loss from these intercompany transactions.

11 TRADE AND OTHER PAYABLES

Trade payables	130,183
Other payables	9,975
	<u>140,158</u>

12 REVENUE

Sales	1,579,175
	<u>1,579,175</u>

13 COST OF REVENUE

Cost of goods sold	1,291,463
	<u>1,291,463</u>

14 GENERAL AND ADMINISTRATIVE EXPENSES

Rent expenses	55,665
Legal and professional fees	29,207
	<u>84,872</u>



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

Significant Accounting Policies : (cont.. page 16)

(figures in U.A.E Dirhams)

From 07.10.2024 to

31.03.2025

15 FINANCE COST

Bank charges	10,881
Interest expense (Related party)	45,260
	<u>56,141</u>

16 FINANCIAL INSTRUMENTS

Financial instruments comprise financial assets and financial liabilities. Financial assets and financial liabilities are recognized on company's balance sheet when it has become a party to the contractual provisions of the instrument. A financial asset is any asset that is cash, contractual right to receive cash or other financial asset, a contractual right to exchange financial instruments under conditions that are potentially favorable or any equity instrument. A financial liability is any liability that is contractual obligation to deliver cash or another financial asset, or to exchange financial instruments under conditions that are potentially un favorable. The fair value of financial assets and financial liabilities equals their carrying values.

(a) Financial Assets

All financial assets are recognized and derecognized on trade date and are initially measured at fair value, plus transaction cost, except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value.

Financial assets are classified into the following specified categories : financial assets are at fair value through profit or loss, held to maturity investments, loans and receivables and available for sale financial assets. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

(b) Financial Liabilities

Financial liabilities are classified as either financial liabilities at fair value through profit or loss or other financial liabilities.

17 RISK MANAGEMENT

Credit Risk

The company's exposure to credit risk is concentrated on bank balances and trade receivables

The company's bank accounts are with local branches of banks operating in the U.A.E. Trade receivables are stated at realizable value net of allowance and bad debts.

(cont...)



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

Significant Accounting Policies : (cont.. page 17)

Liquidity Risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities.

The company has built an appropriate liquidity risk management framework for the management of its short, medium and long term funding and liquidity requirements. The company manages liquidity risk by maintaining adequate reserves and by continuously monitoring forecast and actual cash flows.

Interest risk

There is no borrowing from third party as on balance sheet date. Interest rate risk is minimum.

Exchange Risk

There are no significant exchange rate risks as substantially all financial assets and financial liabilities are denominated in U.A.E Dirhams.

Fair values

At the balance sheet date, the fair values of financial assets and liabilities at year end approximate to their carrying amounts and have been very carefully scrutinized by the management for their correctness.

18 U.A.E. CORPORATE TAX LAW

On 9 December 2022, the UAE Ministry of Finance released the Federal Decree-Law No .47 of 2022 on the Taxation of Corporations and Businesses (the Law) to enact a Federal Corporate Tax (CT) regimen the UAE. The CT regime will become effective for accounting periods beginning on or after 1 June 2023.

The Cabinet of Ministers Decision No.116/2022 effective from January 2023, has confirmed the threshold of income over which the 9% tax rate would apply, and the Law is considered to be substantively enacted. A rate of 9% will apply to taxable income exceeding AED 375,000. A rate of 0% will apply to taxable income not exceeding AED 375,000.

For the Company, current taxes shall be accounted for as appropriate in the financial statements for the period beginning October 07, 2024. In accordance with IAS 12 Income Taxes, the related deferred tax accounting impact has been considered for the financial year ended March 31, 2025.

Since the corporate tax was introduced only recently, this may create tax risks in UAE that are more significant than in other countries. The Company has assessed the deferred tax implications for the year ended March 31, 2025 and, after considering its interpretations of applicable tax law, official pronouncements, cabinet decisions and ministerial decisions (especially with regard to transition rules), it has been concluded that it is not expected to be material.

The Company shall continue to monitor critical Cabinet Decisions to determine the impact on the Company, from deferred tax perspective.



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Notes to the financial statements - for the period ended 31 March 2025

Significant Accounting Policies : (cont.. page 18)

19 COMPARATIVE FIGURES

The fiscal period covers a period of less than 12 months from 07 October 2024 to 31 March 2025.

This period is the first period of operations.

20 APPROVAL OF FINANCIAL STATEMENTS

These financial statements were approved and signed by the shareholder on 24 April 2025.

The attached notes form an integral part of these accounts.

Auditors report is annexed hereto.

For ROSSARI BIOTECH TRADING FZE

Authorized Signatory



ROSSARI BIOTECH TRADING FZE

LB181407A, Jebel Ali Freezone, Dubai, United Arab Emirates

Statement of property, plant and equipments for the period ended 31 March 2025

(figures in U.A.E Dirhams)

7 PROPERTY, PLANT AND EQUIPMENT

	<u>Building</u>	<u>Furniture & Fixtures</u>	<u>Office Equipments</u>	<u>Electrical Equipments</u>	<u>Total</u>
<u>Cost</u>					
Additions during the period	51,450	51,104	735	8,715	112,004
As at 31 March 2025	<u>51,450</u>	<u>51,104</u>	<u>735</u>	<u>8,715</u>	<u>112,004</u>
<u>Accumulated Depreciation</u>					
Charged for the period	281	761	19	130	1,191
As at 31 March 2025	<u>281</u>	<u>761</u>	<u>19</u>	<u>130</u>	<u>1,191</u>
<u>Net Carrying Value</u>					
As at 31 March 2025	<u>51,169</u>	<u>50,343</u>	<u>716</u>	<u>8,585</u>	<u>110,813</u>

